
#### UK Forum for Haemogloblin Disorders 56th Academic Meeting

## Managing chronic pain in sickle patients – a pain physician's perspective



#### **Dr Fauzia Hasnie**

Consultant Lead, Opioid Multidisciplinary Pain Management Clinic Joint Lead, Combined Sickle-Opioid Virtual Multidisciplinary Clinic Guy's & St Thomas' NHS Foundation Trust





#### Outline


- Chronic pain
- Principles of management in chronic pain
- Practical approach to outpatient management of chronic pain in SCD
- Outpatient opioid management
- Considerations in opioid weaning

## Chronic (Persistent) Pain

- >3 Months
- Persists beyond injury and outlasts any potential for healing.
- Maladaptive and negatively impacts on individual & society (significant disability; depression; adverse social consequences).
- Emergence of chronic pain occurs with increasing age.
- 30-40% of adolescents and adults living with SCD suffer from chronic pain.
- SCD chronic pain is multifactorial.
- Mechanisms in persistent pain: nociceptive; neuropathic; nociplastic (coexist in SCD).

## Principles of Management in Chronic Pain (I)

- Patient-centred approach and individualised care matched to patient's needs; understand how pain is affecting their life and vice versa; what is important to them (psychosocial influences).
- **Biopsychosocial model** socioeconomic background, social supports, culture/traditions, faith, attitudes, beliefs, coping skills, learning and memory from previous experiences/past trauma (related or unrelated), personality etc.




## Principles of Management in Chronic Pain (II)

#### Shared-decision making

- increased patient knowledge and satisfaction
- greater involvement in their own care
- more realistic patient expectations
- improved patient compliance to treatment plan
- reduced decisional conflict and anxiety
- improved doctor-patient relationship
- better health outcomes








## Principles of Management in Chronic Pain (III)

- Multidisciplinary/specialty collaborative
- Multimodal pain is complex (biopyschosocial model)
- Goal setting emphasis on function
- Empower **self-management**



## Practical Approach to Outpatient Management of Chronic Pain in SCD



## Practical Approach to Outpatient Management of Chronic Pain in SCD





## American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain

Amanda M. Brandow, <sup>1</sup> C. Patrick Carroll, <sup>2</sup> Susan Creary, <sup>3</sup> Ronisha Edwards-Elliott, <sup>4</sup> Jeffrey Glassberg, <sup>5</sup> Robert W. Hurley, <sup>6,7</sup> Abdullah Kutlar, <sup>8</sup> Mohamed Seisa, <sup>9</sup> Jennifer Stinson, <sup>10</sup> John J. Strouse, <sup>11,12</sup> Fouza Yusuf, <sup>13</sup> William Zempsky, <sup>14</sup> and Eddy Lang <sup>15</sup>

<sup>1</sup>Section of Hematology/Oncology/Bone Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD; <sup>3</sup>Center for Innovation in Pediatric Practice, Division of Hematology, Oncology and Bone Marrow Transplant, Nationwide Children's Hospital, The Ohio State University School of Medicine, Columbus, OH; <sup>4</sup>Department of Pediatrics, University of Illinois at Chicago, Chicago, IL; <sup>5</sup>Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; <sup>6</sup>Department of Anesthesiology and <sup>7</sup>Department of Public Health Sciences, Wake Forest School of Medicine, Winston Salem, NC; <sup>8</sup>Center for Blood Disorders, Medical College of Georgia, Augusta University, Augusta, GA; <sup>9</sup>Mayo Clinic Evidence-based Practice Research Program, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN; <sup>10</sup>Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada; <sup>11</sup>Division of Hematology, Department of Medicine, and <sup>12</sup>Division of Pediatric Hematology/Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC; <sup>13</sup>Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; <sup>14</sup>Division of Pain and Palliative Medicine, Connecticut Children's Medical Center, Department of Pediatrics, University of Connecticut School of Medicine, Hartford, CT; and <sup>15</sup>Department of Emergency Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

**Background:** The management of acute and chronic pain for individuals living with sickle cell disease (SCD) is a clinical challenge. This reflects the paucity of clinical SCD pain research and limited understanding of the complex biological differences between acute and chronic pain. These issues collectively create barriers to effective, targeted interventions. Optimal pain management requires interdisciplinary care.

**Objective:** These evidence-based guidelines developed by the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in pain management decisions for children and adults with SCD.



### America manager

Amanda M. Brai Abdullah Kutlar.

<sup>1</sup>Section of Hematol Behavioral Sciences Transplant, Nationwic IL; 5Department of E Wake Forest School Practice Research P Sciences Research. Nursing, University o Pediatrics, Duke Unit Medicine, Connectic Medicine, Cumming School of Medicine, Onliversity of Sargary, Sargary, AS,

18 Recommendations specific to acute and chronic pain. Low certainty evidence (extrapolated from OA/FM studies) for:

- + NSAIDs
- Duloxetine (SNRI)
- + TCA
- **+** Gabapentinoids
- + CBT
- Other integrative approaches (massage/ acupuncture)

Overall recommend against COT

isease:

Lang<sup>15</sup> Psychiatry and Bone Marrow hicago, Chicago, Health Sciences, Evidence-based artment of Health berg Faculty of Department of and Palliative of Emergency

6,7

Background: The management of acute and chronic pain for individuals living with sickle cell disease (SCD) is a clinical challenge. This reflects the paucity of clinical SCD pain research and limited understanding of the complex biological differences between acute and chronic pain. These issues collectively create barriers to effective, targeted interventions. Optimal pain management requires interdisciplinary care.

Objective: These evidence-based guidelines developed by the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in pain management decisions for children and adults with SCD.




Contents lists available at ScienceDirect

#### Critical Reviews in Oncology / Hematology

journal homepage: www.elsevier.com/locate/critrevonc







<sup>&</sup>lt;sup>a</sup> Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA



b School of Nursing, University of Michigan, Ann Arbor, MI, USA



Contents lists available at ScienceDirect

#### Critical Reviews in Oncology / Hematology



iοι

Comparison of two **VIT D SUPPLEMENTATION** strategies in children (n=38) => no difference in MSK pain or QOL

Chronic pain management in sickle cell disease: A systematic scoping

updates

INHALED CANNABIS, patients also on long-term opioids (n=23)
=> no difference in pain

Cofield b,

**HYPNOSIS** 30 min session (n=14) => no difference in pain

**MULTIMEDIA EDUCATION PROGRAMME** (n=228)

=> no difference in pain

<sup>&</sup>lt;sup>a</sup> Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA

b School of Nursing, University of Michigan, Ann Arbor, MI, USA



Contents lists available at ScienceDirect

#### Critical Reviews in Oncology / Hematology



**HYDROTHERAPY/ PHYSIOTHERAPY** (n=10) => **IMPROVEMENT IN HIP/LBP** 

Chronic pain management in sickle cell disease: A systematic scoping



re

**MINDFULNESS** (n=34) => **DECREASE in PAIN CATASTROPHISING** 

Da<sup>r</sup> Ra

CBT (single session + homework for 8/52) (n=23) => USE OF CBT SKILLS ON DAYS WITH HIGHER PAIN LED TO REDUCTION IN NEXT DAY PAIN INTENSITY

<sup>&</sup>lt;sup>a</sup> Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA

b School of Nursing, University of Michigan, Ann Arbor, MI, USA

# Treating Chronic Pain in Sickle Cell Disease — The Need for a Biopsychosocial Model

Janet E. Childerhose, Ph.D., Robert M. Cronin, M.D., Maryanna D. Klatt, Ph.D., and Andrew Schamess, M.D.

Chronic pain is the most common complication affecting adults with sickle cell disease (SCD).¹ Pain profoundly affects people's quality of life, functional ability, and health care utilization. Clinicians are often unsuccessful at addressing chronic pain in SCD, especially among the large number of patients for whom nonopioid analgesics aren't sufficient and those who have developed opioid tolerance. Why aren't we doing better?

We believe the medical community is looking at sickle cell pain through the wrong lens — treating it as a hematologic problem, while overlooking the neurologic, psychological, and social aspects of chronic pain. Given the current understanding of the neuropsychology of pain, the health care system has the ability to manage sickle cell pain more effectively. Doing so will require accepting a broader understanding of the experience of pain and

devoting adequate resources to addressing its multiple dimensions.

The biopsychosocial model helps capture people's experience of chronic pain by affirming that biologic, neuropsychological, and socioenvironmental elements play a role in pain-related processes. Biologically, acute vaso-occlusive events in SCD cause tissue inflammation and nociceptive pain. This concept remains the primary model used in clinical prac-

## Practical Approach to Outpatient Management of Chronic Pain in SCD



## Practical Approach to Outpatient Management of Chronic Pain in SCD (I)

- Doctor-patient relationship
- **Expectation** management explore patient's expectation of visit; 'useful/meaningful' pain relief rather than cure; expectation of outcomes from interventions, drug therapy etc; expectation that passive rather than active treatment will be beneficial (yellow flags)
- Education and empower.
- 'Back to basics' approach underlies pain management (healthy diet, healthy lifestyle).
- Importance of movement/ physical therapies (e.g. group exercise programme especially combined with conventional medical management) - aim is to reduce deconditioning, functional impairment and maladaptive behaviour; to desensitise and break fear-avoidance cycle; avoid boom-bust cycle (pacing); and to reactivate.
- Psychological therapies individual/PMP/(inpatient) based on ACT.

## Practical Approach to Outpatient Management of Chronic Pain in SCD (II)

#### Pharmacological

- Represents small part of overall pain management and is the least changeable option
- Potential drug interactions/risk multipliers
- Mechanism-based approach...practical pain management is often limited by tolerability
- Other issues with tolerance, dependence, misuse, addiction.
- Aim to rationalise, optimise & educate.



## Practical Approach to Outpatient Management of Chronic Pain in SCD (III)

- Interventions (e.g. targeted injections)
  - rationale, benefit & risks
  - predictors of poor outcome yellow flags

    - widespread pain
    - no clear target
    - no correlation clinically and radiologically
    - pain behaviours
    - high anxiety/psychologically vulnerable/ unstable mental health
    - high dose opioids (OIH)/ drug dependency
    - ongoing litigation
    - if patient is undecided
- Alternative acupuncture, TENS



# Principles of Outpatient Opioid Management in SCD Opioid Trial/ COT



- Weigh up risk: benefit
- Risk of aberrant medication-related behaviour & yellow flags (risk factors for opioid misuse)
- Risk of long-term side-effects
- Implications of tolerance and dependence
- Alternatives/ adjuncts: non-opioid; non-pharmacological
- Lowest effective dose
- Risk of harm with no added benefit (>120mg OME) & caution with risk multipliers
- Tolerability managing common side-effects (GI)
- Regular review to assess improvement in function & QOL
- Consider tapering...

## General Considerations in Opioid Weaning...



- When to taper or stop?
- Preparation for dose reduction?
- Strategies for outpatient weaning?





- If the medication is not providing 'meaningful' pain relief or improvement in function..
- If the patient develops intolerable side-effects risk of harm escalates with no added benefit ≥120mg oral morphine equivalent/24hours.
- If misuse or concern regarding aberrant drug-related behaviour.
- If there is strong evidence that the patient is diverting his/her medications to others.



## (2) Preparation for Dose Reduction

- Motivation to wean.
- Explanation of rationale for tapering opioids including potential benefits of opioid reduction (avoidance of long-term harms and improvement in ability to engage in self-management strategies).
- Patient information leaflet
- Agreeing outcomes of opioid tapering.
- Support during tapering (including psychology support for mental health co-morbidities) and arrangements for follow-up (nurse/mdt).
- Anticipate and address specific concerns regarding opioid withdrawal and rebound pain.
- Close collaboration between the patient, his or her carers, GP, other specialty teams.
- Agree prescribing responsibilities.
- Role of Drug & Alcohol Service to support dose reduction.



## (3) Outpatient Weaning

- Immediate release vs sustained.
- Liquid to tablets.
- Dosing interval: scheduled rather than PRN to avoid toxicity-withdrawal/ frequency.
- Rate of wean: 10% of total daily dose every 1-2 weeks
- Opioid rotation if unable to taper on existing opioid regime reduce total OME by 25-30% to account for incomplete cross-tolerance.
- Frequency of pharmacy dispensing: weekly, alternate day or daily
- Named GP prescriber
- Education on withdrawal and strategies (taper more slowly; Lofexidine/ Clonidine).
- Reassurance regarding rebound pain
- Non-opioid adjuvants gabapentinoids are opioid-sparing (caution with polypharmacy)
- Non-opioid strategies (psychological support/TENS)

# UK – Opioids Aware (I) www.fpm.ac.uk/faculty-of-pain-medicine/opioids-aware

- FPM/RCoA launched 'Opioids Aware' in 2016
- Evidence-based online prescribing resource to support healthcare professionals & patients
- Broad support developed in collaboration with medical royal colleges, RPS, BPS, Public Health England, NHS England, NICE, CQC
- Links to other sources
- Doses >120mg OME risk of harm escalates with no added benefit
- Avoid prescribing 'risk multipliers' (BDZ, Pregabalin)



## Thank you

